Report of the Ad Hoc Committee on Drug Product Selection of the Academy of General Practice of Pharmacy and the Academy of Pharmaceutical Sciences

Doluisio, James T.; Fedder, Donald O.; Manley, Gary; Mattei, Thomas J.; Nightengale, Charles; Barr, William

doi:10.1016/s0003-0465(16)32601-5

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phenytoin is one of the more widely used non-sedative anticonvulsants. It is effective in most forms of epilepsy except absence seizures (I) and has been classified as a drug with 'high risk potential' with respect to bioavailability problems (2). The generally accepted therapeutic range for phenytoin is 10-20pg~ml (3,4), although adequate seizure control in individual patients may fall outside this range (5).…”

Section: Introductionmentioning

confidence: 99%

Comparison of the effectiveness of two oral phenytoin products and chronopharmacokinetics of phenytoin

Petker

Morton

1993

J Clin Pharm Ther

View full text Add to dashboard Cite

A cross-over study was carried out in 14 epileptic patients to compare the steady-state serum phenytoin concentrations produced by two phenytoin formulations (Phenytoin Sodium and Epanutin). Differences in steady-state phenytoin concentrations following a change from one product to the other were not significant, indicating that the two brands manifest equivalent therapeutic efficacy. The results suggest that no overall dosage adjustments are required when switching from one brand to the other. Chronopharmacokinetic parameters of a single 300-mg dose of phenytoin, given at 08.00 and 20.00 hours, were studied in 10 healthy, male volunteers under controlled conditions. No evidence was found that circadian rhythms influenced absorption and disposition.

show abstract

Section: Introductionmentioning

confidence: 99%